19 related articles for article (PubMed ID: 18322441)
1. Alopecia with endocrine therapies in patients with cancer.
Saggar V; Wu S; Dickler MN; Lacouture ME
Oncologist; 2013; 18(10):1126-34. PubMed ID: 24037977
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.
Marra M; Sordelli IM; Lombardi A; Lamberti M; Tarantino L; Giudice A; Stiuso P; Abbruzzese A; Sperlongano R; Accardo M; Agresti M; Caraglia M; Sperlongano P
J Transl Med; 2011 Oct; 9():171. PubMed ID: 21985599
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.
Caraglia M; Giuberti G; Marra M; Addeo R; Montella L; Murolo M; Sperlongano P; Vincenzi B; Naviglio S; Prete SD; Abbruzzese A; Stiuso P
Cell Death Dis; 2011 Apr; 2(4):e150. PubMed ID: 21525937
[TBL] [Abstract][Full Text] [Related]
4. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
6. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
[TBL] [Abstract][Full Text] [Related]
8. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
9. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature.
Gill ML; Atiq M; Sattar S; Khokhar N
J Pak Med Assoc; 2005 Apr; 55(4):135-8. PubMed ID: 15918622
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
